Emerg Infect DisEmerging Infect. DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for Disease Control and Prevention22515845335807511-101810.3201/eid1805.111018Letters to the EditorLetterHigh Anti–Phenolic Glycolipid-I IgM Titers and Hidden Leprosy Cases, Amazon RegionHidden Leprosy Cases, Amazon RegionSalgadoClaudio GuedesFerreiraDenis Vieira GomesFradeMarco Andrey CiprianiGuimarãesLayana de SouzaBatista da SilvaMoisésBarretoJosafá GonçalvesFederal University of Pará, Marituba, Brazil (C.G. Salgado, D.V.G. Ferreira, L.S. Guimarães, M.B. Silva, J.G. Barreto);Federal University of Pará, Belém, Brazil (C.G. Salgado, M.B. Silva);São Paulo University–Faculty of Medicine, São Paulo, Brazil (M.A.C. Frade);Dr Marcello Candia Reference Unit in Sanitary Dermatology of the State of Pará, Marituba (L.S. Guimarães);Federal University of Pará, Castanhal, Brazil (J.G. Barreto)Address for correspondence: Claudio Guedes Salgado, Laboratório de Dermato-Imunologia UEPA/UFPA/MC, Av João Paulo II, 113, Bairro Dom Aristides, CEP: 67200-000, Marituba, Pará, Brazil; email: csalgado@ufpa.br52012185889890Keywords: leprosyserologyPGL-Isubclinical infectionbacteriaHansen diseaseMycobacterium lepraeAmazon RegionIgMtitersseroprevalence

To the Editor: Leprosy remains a serious public health issue. Although the World Health Organization elimination target was achieved in 2000, with a prevalence of <1 case/10,000 persons, despite progress since introduction of multidrug therapy (1), large pockets of poverty remain in which the disease is hyperendemic and underdiagnosed. In fact, in highly disease-endemic areas, the prevalence of previously undiagnosed leprosy cases in the general population has been reported to be 6× higher than the registered prevalence (2).

Most leprosy patients are in India and Brazil. In Brazil, new cases are concentrated in the Northeast, Midwest, and Amazon regions (from state capitals to the inner counties). Access to the health system is poor in these regions because of severe inequalities in the public health system of Brazil (3),

A total of 34,894 new cases were registered in Brazil during 2010 (4), corresponding to an incidence rate of 18.22 cases per 100,000 population. Pará State accounted for 10.2% of cases (3,562 cases), an incidence rate of 46.93 per 100,000 population. When only children <15 years of age were considered, Pará registered 389 new cases of leprosy in 2010, representing 10.9% of all cases, an incidence rate of 16.52 per 100,000 population. In Oriximiná, a county with 62,794 inhabitants in northwestern Pará, ≈800 km from Belém, Pará’s capital, a mean of 13.8 cases per year were registered for the past 5 years.

In 2010, in Oriximiná, we collected plasma samples from 138 students 8–18 years of age, from 35 leprosy patients who received a diagnosis during 2004–2009, and from 126 contacts of these patients (Federal University of Pará Research Ethics Committee protocol no. 197/07). We tested all of these samples for anti–phenolic glycolipid-I (PGL-I) IgM; 42% of students, 54.3% of case-patients, and 45% of case-patient contacts were seropositive. In addition to collecting samples, we clinically examined the leprosy patients and their contacts, among whom we identified 3 new leprosy cases. We did not examine students at that time. Contacts were persons from the same household or neighborhood whom the index case-patient described as a person with whom he or she had a close relationship. Leprosy cases were diagnosed in the field on the basis of clinical signs, loss of sensation on the skin lesions, and presence of enlarged nerves. For operational reasons, skin smears were not performed. All cases were diagnosed by 2 leprologists. We used the Ridley-Jopling classification, associated with the indeterminate clinical type, as defined by the Madrid classification. The ELISA cutoff for positive results was arbitrarily established as an optical density of 0.295 based on the average plus 3× the SD of the test results from 14 healthy persons from the Amazon region (5).

Because studies of the seroprevalence among contacts have reported a proportion of seropositive persons ranging from ≈1.9% to 18.4% (6), we returned to Oriximiná 16 months after the first visit. We examined 2 groups of students and their contacts; 1 group was positive for anti–PGL-I, and the other group was negative for anti–PGL-I. We visited 44 households in 1 week. From the 35 leprosy patients encountered during the first visit, we selected 25 households to survey (14 with an anti–PGL-I–positive contact in the household and 11 without), and among students with results of anti–PGL-I serology, we selected 19 households (11 positive with an anti–PGL-I–positive contact in the household and 8 without). During our visits to all of these households, we examined 222 persons (Table).

New leprosy cases detected among selected households, Oriximiná, Pará State, Brazilian Amazon, 2010
GroupHousehold contact anti–PGL-I IgM ELISA resultNo. households visitedNo. persons examinedNo. new cases
Among persons previously testedAmong contacts of persons previously testedTotal†
Leprosy patientsPositive14439413
Negative1142112
StudentsPositive11845510
Negative853145
Total44222161430

*Households were selected from among 35 leprosy patients encountered during the first visit (25 households, 14 with an anti–PGL-I–positive contact in the household and 11 without) and among students with results of anti–PGL-I serology (19 households, 11 with an anti–PGL-I–positive contact in the household and 8 without). PGL-I, phenolic glycolipid-I.
†Fisher exact test comparing case-patients and non–case-patients among those positive or negative for anti-PGL-I IgM revealed a statistically significant difference (p = 0.0280).

When we arrived in Oriximiná, only 2 cases had been registered in the national notifiable diseases information system. By using our approach, 23 new cases were found after we investigated households that had a person positive for anti–PGL-I (15 multibacillary, 8 paucibacillary); we found only 7 new cases in households where residents were negative for anti–PGL-I (4 multibacillary, 3 paucibacillary) (Table). For comparison, during the last traditional leprosy campaign in Oriximiná in 2008, eight new cases were detected. Furthermore, by using our strategy, the local public health service detected 9 additional new cases during the 4 months after our departure from Oriximiná.

These data emphasize that contact examination is crucial for identifying new cases (7) and that such investigation must be conducted periodically. Our data also indicate that subclinical infections are highly prevalent among public school students in the Amazon region and that identifying students with positive anti–PGL-I test results can lead to discovery of new leprosy cases among students’ household contacts.

Suggested citation for this article: Salgado CG, Ferreira DVG, Frade MAC, Guimarães LDS, da Silva MB, Barreto JG. High anti–PGL-I IgM titers and hidden leprosy cases, Amazon region. Emerg Infect Dis [serial on the Internet]. 2012 May [date cited]. http://dx.doi.org/10.3201/eid1805.111018

Acknowledgments

We thank André Luiz Correa de Sousa, Márcia Leão, and Anna Elizabeth Martins Alves for collecting the samples and data from the patients; Sabrina Sampaio Bandeira for the patient impairment evaluation; Domingos Diniz, Miguel Canto, and the Programa de Ação Interdiciplinar at Oriximiná for logistical support and fruitful discussions; John Spencer for supplying the native PGL-I and technical support with the ELISA; the Oriximiná health secretary and community health agents; and the study participants.

C.G.S. designed and coordinated the study; clinically examined, diagnosed, and classified the subjects; statistically analyzed the data; and wrote the manuscript. D.V.G.F. collected and processed the samples, performed laboratory assays, and statistically analyzed the data. M.A.C.F. clinically examined, diagnosed leprosy, and classified the subjects. L.S.G. evaluated the functional statuses of the subjects. M.B.S. performed laboratory assays. J.G.B. designed the study and interviewed the participants. All authors participated in the interpretation of the data and read and approved the final manuscript.

This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ: neglected diseases grant 576425/2008-7 and scholarship for C.G.S.), by the Secretaria Executiva de Saúde Pública do Estado do Pará and by the Universidade Federal do Pará.

ReferencesBurki T. Old problems still mar fight against ancient disease. Lancet. 2009;373:2878 10.1016/S0140-6736(09)60083-019177600Moet FJ, Schuring RP, Pahan D, Oskam L, Richardus JH. The prevalence of previously undiagnosed leprosy in the general population of northwest Bangladesh. PLoS Negl Trop Dis. 2008;2:e198 10.1371/journal.pntd.000019818301731Penna G, Pinto L, Soranz D, Glatt R. High incidence of diseases endemic to the Amazon region of Brazil, 2001–2006. Emerg Infect Dis. 2009;15:62632 10.3201/eid1504.08132919331758World Health Organization. Leprosy update, 2011. Wkly Epidemiol Rec. 2011;86:3899921887885Barreto JG, Guimarães LS, Leão MRN, Ferreira DVG, Lima RAA, Salgado CG. Anti-PGL-I seroepidemiology in leprosy cases: household contacts and school children from a hyperendemic municipality of the Brazilian Amazon. Lepr Rev. 2011;82:3587022439276Moura RS, Calado KL, Oliveira ML, Büher-Sékula S. Leprosy serology using PGL-I: a systematic review. Rev Soc Bras Med Trop. 2008;41(Suppl 2):118 10.1590/S0037-8682200800070000419618069World Health Organization. Enhanced global strategy for further reducing the disease burden due to leprosy (plan period: 2011-2015). New Delhi (India): WHO Regional Office for South-East Asia; 2009